Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Simona Pagliuca, MD, Yihong Guan, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Metis Hasipek, PhD, Laila Terkawi, Misam Zawit, MBBS, Hassan Awada, MD, Valeria Visconte, PhD, Yogenthiran Saunthararajah, MD, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-143094

Published: 2020

Journal Articles

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, PhD, Anand D. Tiwari, PhD, Xiaorong Gu, PhD, Jason Valent, MD, Jaroslaw Maciejewski, PhD, Frederic Joel Reu, James G Phillips, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142847

Published: 2020

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Blood (2019) 134 (Supplement_1): 2472.

https://doi.org/10.1182/blood-2019-129056

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Targeting NAD + Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure

Phillip J Maciejewski, Yihong Guan, Metis Hasipek, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, James G Phillips, PhD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2018-99-119300

Published: 2018

Journal Articles

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, James G Phillips, PhD, Jaroslaw P. Maciejewski, Hetty E. Carraway, MD MBA, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2018-99-118924

Published: 2018

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD, Charlotte Jarman, Anand D. Tiwari, PhD, James G Phillips, PhD, Caroline Schuerger, Babal K. Jha, Yogenthiran Saunthararajah, MD

Blood (2018) 132 (Supplement 1): 216.

https://doi.org/10.1182/blood-2018-99-119311

Published: 2018

Journal Articles

Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms

Vera Adema, PhD, Suresh K. Balasubramanian, MD, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, James G Phillips, PhD, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 106.

https://doi.org/10.1182/blood.V130.Suppl_1.106.106

Published: 2017

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

Metis Hasipek, PhD, Sayer Al-Harbi, PhD, James G Phillips, PhD, Bartlomiej P. Przychodzen, MSc, Alek Nielsen, BS, Yihong Guan, PhD, Dale Grabowski, BS, Phillip J Maciejewski, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD

Blood (2017) 130 (Supplement 1): 2654.

https://doi.org/10.1182/blood.V130.Suppl_1.2654.2654

Published: 2017

Journal Articles

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Valeria Visconte, PhD, James G Phillips, PhD, Bartlomiej P Przychodzen, MSc, Jaroslaw P Maciejewski, MD PhD FACP, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 525.

https://doi.org/10.1182/blood.V128.22.525.525

Published: 2016

Journal Articles

The GLI-Code As a Potential Therapeutic Target in Myeloid Neoplasms

Sayer Alharbi, PhD, Alek d Nielsen, B.S., Metis Hasipek, PhD, Bartlomiej P Przychodzen, MSc, James G Phillips, PhD, Jaroslaw P Maciejewski, MD PhD FACP, Babal Jha, PhD

Blood (2016) 128 (22): 1655.

https://doi.org/10.1182/blood.V128.22.1655.1655

Published: 2016

Journal Articles

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Sergei Vatolin, PhD, James G Phillips, PhD, Shravya Govindgari, Dale Grabowski, Yvonne Parker, Daniel Lindner, MD PhD, Claudiu Cotta, MD PhD, Frederic J. Reu, MD

Blood (2014) 124 (21): 2085.

https://doi.org/10.1182/blood.V124.21.2085.2085

Published: 2014

NARROW

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Targeting NAD + Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Novel Therapeutic Targets for DNMT3A Mutant Myeloid Neoplasms

Activation of Autophagy in Models of SF3B1 Mutant MDS

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

The GLI-Code As a Potential Therapeutic Target in Myeloid Neoplasms

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only